0RQE Stock Chart & Stats
CHF6.63
CHF0.47(7.54%)
At close: 4:00 PM EDT
CHF6.63
CHF0.47(7.54%)
Day’s Range― - ―
52-Week RangeCHF2.42 - CHF7.55
Previous CloseN/A
Volume312.22K
Average Volume (3M)510.70K
Market Cap
CHF1.60B
Enterprise ValueCHF3.01K
Total Cash (Recent Filing)CHF88.69M
Total Debt (Recent Filing)CHF1.32B
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Oct 29, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding263,059,780
10 Day Avg. Volume952,249
30 Day Avg. Volume510,700
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-0.80
Price to Sales (P/S)4.14
P/FCF Ratio-5.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF5.25Price Target Upside-20.81% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.57
Revenue Forecast (FY)CHF207.04M
Bulls Say, Bears Say
Bulls Say
High Gross Margin (~81%)An ~81% gross margin indicates structurally high product-level profitability and potential pricing power or low COGS. If Idorsia can stabilize revenues, this margin affords operating leverage: incremental sales translate strongly to improved gross profit, aiding long-term cash generation once fixed R&D/SG&A pressures moderate.
Diversified Revenue Model: Sales + LicensingHaving both product sales and partnership/licensing income diversifies cash sources and reduces reliance on a single revenue stream. Milestones, upfronts and royalties provide non-linear, sometimes lumpy inflows that can fund R&D or bridge cash needs, lowering structural funding risk if partnerships continue to deliver.
Commercial Products Plus Clinical PipelineIdorsia operates both marketed medicines and a clinical-stage pipeline across cardiovascular, CNS and immunological areas. Commercial sales give an existing go-to-market base while multiple pipeline programs create several medium-term value inflection points (approvals, partnerships) that can sustainably expand revenues and geographic reach.
Bears Say
Highly Stressed Balance SheetMaterially negative equity and large debt relative to a modest asset base sharply constrain financial flexibility. This increases refinancing and covenant risk, makes access to non-dilutive capital harder, and can force strategic compromises (asset sales, alliance terms, or reduced R&D) unless capital structure remediation occurs.
Sustained Negative Cash GenerationPersistent negative operating and free cash flows mean the company is consuming cash to run operations and advance programs. Over a multi-month horizon this necessitates external funding, partnering or milestone receipts; prolonged burn raises dilution or refinancing risk and can delay clinical or commercial investments.
Deep Operating Losses And Declining RevenueSteep negative margins and falling revenues reflect that core operations are not yet profitable or scaling. This limits the company's ability to self-fund growth, threatens debt servicing capacity, and implies that absent sustained revenue recovery or cost restructuring, losses will continue to pressure liquidity and strategic options.
0RQE FAQ
What was Idorsia Ltd’s price range in the past 12 months?
Idorsia Ltd lowest share price was CHF2.42 and its highest was CHF7.55 in the past 12 months.
What is Idorsia Ltd’s market cap?
Idorsia Ltd’s market cap is CHF1.60B.
When is Idorsia Ltd’s upcoming earnings report date?
Idorsia Ltd’s upcoming earnings report date is Oct 29, 2026 which is in 83 days.
How were Idorsia Ltd’s earnings last quarter?
Idorsia Ltd released its earnings results on Jul 30, 2026. The company reported -CHF0.165 earnings per share for the quarter, beating the consensus estimate of -CHF0.195 by CHF0.03.
Is Idorsia Ltd overvalued?
According to Wall Street analysts Idorsia Ltd’s price is currently Overvalued.
Does Idorsia Ltd pay dividends?
Idorsia Ltd does not currently pay dividends.
What is Idorsia Ltd’s EPS estimate?
Idorsia Ltd’s EPS estimate is -0.27.
How many shares outstanding does Idorsia Ltd have?
Idorsia Ltd has 263,059,780 shares outstanding.
What happened to Idorsia Ltd’s price movement after its last earnings report?
Idorsia Ltd reported an EPS of -CHF0.165 in its last earnings report, beating expectations of -CHF0.195. Following the earnings report the stock price went down -5.64%.
Which hedge fund is a major shareholder of Idorsia Ltd?
Currently, no hedge funds are holding shares in GB:0RQE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat psoriasis; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; and collaboration with Viatris Inc. to develop and commercialize selatogrel and cenerimod. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
0RQE Stock 12 Month Forecast
Average Price Target
CHF5.25
▼(-20.81% Downside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Kuros Biosciences
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―